Your browser doesn't support javascript.
loading
Impact of Pacemaker Implantation After Transcatheter Aortic Valve Replacement on Long-Term Survival in Patients With Bicuspid Aortic Valve.
De Felice, Francesco; Paolucci, Luca; Cesario, Vincenzo; Musto, Carmine; Nazzaro, Marco Stefano; Chin, Diana; Stio, Rocco; Pennacchi, Mauro; Gabrielli, Domenico; Fiorina, Claudia; Massussi, Mauro; Angelillis, Marco; Costa, Giulia; Bruschi, Giuseppe; Fineschi, Massimo; Maffeo, Diego; Barletta, Marta; Regazzoli, Damiano; Montorfano, Matteo.
  • De Felice F; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy. Electronic address: FDeFelice@scamilloforlanini.rm.it.
  • Paolucci L; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Cesario V; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Musto C; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Nazzaro MS; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Chin D; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Stio R; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Pennacchi M; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Gabrielli D; Interventional Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
  • Fiorina C; Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
  • Massussi M; Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
  • Angelillis M; Catheterization Laboratory, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Costa G; Catheterization Laboratory, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
  • Bruschi G; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Fineschi M; Interventional Cardiology UOSA, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
  • Maffeo D; Interventional Cardiology Unit, Fondazione Poliambulanza, Brescia, Italy.
  • Barletta M; Clinical and Interventional Cardiology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Donato, San Donato Milanese, Milan, Italy.
  • Regazzoli D; Humanitas Research Hospital Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rozzano, Italy.
  • Montorfano M; School of Medicine, Vita-salute San Raffaele University, Milan, Italy; Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute, Milan, Italy.
Am J Cardiol ; 210: 146-152, 2024 01 01.
Article en En | MEDLINE | ID: mdl-37838072
ABSTRACT
Limited data are available about the impact of permanent pacemaker (PPM) implantation on long-term survival in patients with a bicuspid aortic valve (BAV) and severe aortic stenosis (AS) treated with transcatheter aortic valve replacement (TAVR). We aimed to evaluate the long-term clinical outcomes of patients with BAV with AS who underwent periprocedural PPM implantation after TAVR with a self-expandable prosthesis. Data from patients with BAV and severe AS who underwent TAVR between April 2009 and January 2022 and followed in the framework of the One Hospital ClinicalService-CoreValve Project were collected. Patients were categorized in 2 groups according to PPM implantation after TAVR ("PPM" group) or not ("no PPM" group). The coprimary end points were all-cause death and a composite of cardiac mortality, rehospitalization because of cardiac causes, stroke, and myocardial infarction. Overall, 106 patients were considered (74 in the "no PPM" group and 32 in the "PPM" group). No statistically significant difference was found between the groups in terms of follow-up and baseline characteristics. Patients in the PPM group were more likely to show baseline conduction abnormalities (p = 0.023). Patients in the PPM group were more often treated with older generation prosthesis than those in the no PPM group (28.1% vs 5.4%, respectively, p = 0.013). At 2 years of follow-up, all-cause death in the no PPM and PPM groups occurred in 20.0% and 10.0% of patients, respectively (hazard ratio 0.37, 95% confidence interval 0.08 to 1.67). Similarly, no difference was evident for the composite end point between the 2 groups (no PPM vs PPM 8 [14.6%] vs 6 [19.3%], hazard ratio 1.67, 95% CI 0.58 to 4.81). In conclusion, patients with severe AS and BAV treated with TAVR complicated by PPM implantation are not exposed to an increased risk of major adverse events at 2 years of follow-up.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Estenosis de la Válvula Aórtica / Marcapaso Artificial / Reemplazo de la Válvula Aórtica Transcatéter / Enfermedad de la Válvula Aórtica Bicúspide Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Estenosis de la Válvula Aórtica / Marcapaso Artificial / Reemplazo de la Válvula Aórtica Transcatéter / Enfermedad de la Válvula Aórtica Bicúspide Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article